Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy

BACKGROUND: Failure to CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), is an emerging clinical problem. There is no consensus on the treatment for these patients and treatment remains empirical. CASE RE...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Weiguo, Tao, Shi, Miao, Wenchun, Liu, Hui, Yuan, Xianggui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226330/
https://www.ncbi.nlm.nih.gov/pubmed/35757723
http://dx.doi.org/10.3389/fimmu.2022.894787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226330/
https://www.ncbi.nlm.nih.gov/pubmed/35757723
http://dx.doi.org/10.3389/fimmu.2022.894787

Ejemplares similares